The Claim
In the 5xFAD transgenic mouse model, which lacks tau aggregation, cerebrospinal fluid total tau levels increase concurrently with amyloid-beta accumulation, indicating that amyloid pathology alone is sufficient to drive soluble tau release without tau aggregation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In genetically modified mice that develop amyloid plaques but not tau tangles, levels of soluble tau in the cerebrospinal fluid rise as amyloid-beta accumulates, showing that amyloid pathology can trigger soluble tau release without the presence of tau aggregates.
See the scientific wording
In a transgenic mouse model (5xFAD) that does not develop tau aggregates, CSF total tau increases in parallel with amyloid-beta accumulation, demonstrating that amyloid pathology alone can drive soluble tau release independent of tau aggregation.
When amyloid-beta builds up in the brain, it stresses neurons, causing them to add extra phosphate groups to tau protein. This makes tau detach from its normal structure and leak out of the neurons into the fluid surrounding the brain. The amount of tau in this fluid rises as amyloid-beta increases, even when tau never forms clumps.
What the research says
1 studyIn mice that only get amyloid plaques but not tau tangles, the fluid around their brain still shows more tau as the plaques grow — proving amyloid can make tau float free without turning it into clumps.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.